The Economic Contribution of Industry-Sponsored Pharmaceutical Clinical Trials

Tran, Dat T.; Akpinar, Ilke; Fedorak, Richard N.; Jonsson, Egon; Mackey, John R.; Richer, Lawrence; Jacobs, Philip

doi:10.18433/j3dh0v

Cited by 5 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the range of total costs calculated through the sensitivity analyses should capture the uncertainty associated with these assumptions. Lastly, we estimated management and patient service billings from contracts of a small number of industry-sponsored drug CTs conducted in Northern Alberta [2] and we adjusted these for wage differentials between provinces. We assumed that patterns of care are similar throughout the country.…”

Section: Discussionmentioning

confidence: 99%

“…We conducted an analysis using the Aggregate Analysis of ClinicalTrials.gov (AACT) database [3], which provides rich data elements on each CT, such as the number of enrollees, start and completion dates, treatment regimen, location(s) and funding. The AACT database has been used previously in research [2].…”

Section: Study Design and Data Sourcesmentioning

confidence: 99%

“…We used a previously reported algorithm to estimate the costs of the study drugs [2,4]. Briefly, we first searched for each drug's market price in the Alberta Drug Benefit List (ADBL) [5].…”

Section: Drug Costsmentioning

confidence: 99%

“…The AACT database does not provide cost data. We estimated management and patient service billings for each CT based on a previous report on the economic contribution of industry-sponsored drug CTs in Alberta [2]. The management billings (e.g.…”

Section: Management and Patient Service Billingsmentioning

confidence: 99%

“…the insurer's or consumer's retail price). Nevertheless, there is a cost attributable to all healthcare services received by CT participants [2].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

The Costs of Industry-Sponsored Drug Trials in Canada

Tran

Akpinar

Jacobs

2019

PharmacoEconomics Open

Self Cite

View full text Add to dashboard Cite

Objective The objective of this study was to estimate the provincial and nationwide costs of industry-sponsored drug clinical trials (CTs) in Canada. Methods We used the Aggregate Analysis of ClinicalTrials.gov (AACT) database, and included all industry-sponsored drug CTs that were conducted in Canada and completed in 2016. We estimated the costs of the study drugs using the market price. Estimates of the costs of management and patient services were based on industry contracts. Results The sample included 394 CTs that were conducted in 2039 facilities in Canada and provided services for 20,126 Canadian enrollees. Two-thirds of the CTs (277 of 394) were in the non-cancer category. On average, the drug costs per patient were 89,680 Canadian dollars ($Can) during the lifespan of the CTs, and were higher in cancer CTs than in non-cancer CTs ($Can216,876 vs. $Can65,274). The total costs of industry-sponsored drug CTs completed in 2016 was $Can2093.7 million. Drug costs accounted for the majority of this total ($Can1804.9 million). Ontario ($Can781.2 million) and Quebec ($Can757.5 million) had the highest costs. Conclusion The costs of industry-sponsored drug CTs completed in 2016 when measured in terms of market prices in Canada were valued at $Can2.1 billion.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Study Design and Data Sourcesmentioning

confidence: 99%

Section: Drug Costsmentioning

confidence: 99%

Section: Management and Patient Service Billingsmentioning

confidence: 99%

“…the insurer's or consumer's retail price). Nevertheless, there is a cost attributable to all healthcare services received by CT participants [2].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The Costs of Industry-Sponsored Drug Trials in Canada

Tran

Akpinar

Jacobs

2019

PharmacoEconomics Open

Self Cite

View full text Add to dashboard Cite

show abstract

The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta

Akpinar

Öhinmaa

Thording³

et al. 2019

PharmacoEconomics Open

Self Cite

View full text Add to dashboard Cite

ObjectiveOur objective was to describe the costs of industry-sponsored clinical trials for medical devices in Northern Alberta, Canada.MethodsWe used centralized data to identify all industry-sponsored medical device clinical trials initiated in Northern Alberta from 2012 to 2016. For each arm of each trial, we calculated the price of devices provided by the sponsor and the cost of clinical and administrative services that were incurred to clinically operationalize the treatment.ResultsOur sample consisted of 18 device trials initiated between January 2012 and January 2016. The overall cost (Canadian dollars [$Can], year 2018 values) per enrolee was $Can18,243 for the experimental arm and $Can13,827 for the control arm. Devices were the highest cost component, at $Can13,446 per enrollee in the experimental arm. Clinical costs in the control arms were higher on average ($Can7202 vs. 2504) than those in the experimental arms.ConclusionData from industry-sponsored clinical trials can provide important information on the full costs of device-related interventions. As device costs rise, and as policy makers require more evidence on device-related treatments, the cost of medical device-driven interventions should be documented along with their effectiveness.

show abstract